NMTC Stock Analysis: Buy, Sell, or Hold?
NMTC - NeuroOne Medical Technologies Corporation Common Stock
$2.88
0.13 (4.73%)
▲
5d:
-4.0%
30d:
-15.04%
90d:
+290.51%
BUY
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 13, 2026
30d
Get Alerted When NMTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NMTC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NMTC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NMTC is currently trading at $2.88, which is considered oversold relative to its 30-day fair value range of $3.02 to $3.40.
Technical Outlook: Technically, NMTC is in a strong uptrend. The price is currently testing key support at $3.32. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: NMTC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.93 (+244.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NMTC is in a strong uptrend. The price is currently testing key support at $3.32. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: NMTC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.93 (+244.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.02 -
$3.40
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 244.9% below Wall St target ($9.93)
Trading Range Analysis
30-Day Trading Range
$3.02 -
$3.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.32
Resistance Level
$4.05
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.61
Wall Street Target
$9.93
(+244.9%)
Revenue Growth (YoY)
72.5%
Profit Margin
-52.2%
Share & Embed Analysis
Last updated: July 13, 2026 9:20 AM ET
Data refreshes hourly during market hours. Next update: 10:20 AM
Data refreshes hourly during market hours. Next update: 10:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMTC showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Christianson
SELL
16 shares
2026-03-13
Mark Christianson
SELL
136 shares
2026-03-12
Mark Christianson
SELL
351 shares
2026-03-11
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 66 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 64 BUY |
